BIOMAT Database Logo BIOMAT Database Logo

Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks. 1998

L L Siu, and A M Oza, and E A Eisenhauer, and P S Firby, and J J Thiessen, and M Michael, and N Wainman, and J Manzo, and R Feld, and R A Goldberg, and M J Moore
Department of Medicine, Princess Margaret Comprehensive Cancer Centre, Faculty of Pharmacy, University of Toronto, Ontario, Canada.

OBJECTIVE 9-Aminocamptothecin (9-AC) is a water-insoluble camptothecin (CMP) derivative that inhibits normal topoisomerase I function. Schedule dependency was noted, with the greatest activity seen in the setting of greater than 24 hours exposure to lactone (L) concentrations > or = 10 nmol/L. In this phase I study, 9-AC was given by a continuous intravenous infusion over 24 hours once weekly times four every 5 weeks. METHODS Twenty patients, of whom 16 had fluorouracil-refractory colorectal cancer (CRC), entered the study. Dose levels were 0.7 mg/m2 (n = 4), 1.4 mg/m2 (n = 3), 1.9 mg/m2 (n = 6), and 1.65 mg/m2 (n = 7). Detailed pharmacokinetic (PK) measurements of 9-AC L and carboxylate (C) were performed on day 1 of cycles 1 and 2. RESULTS At 1.9 mg/m2, dose-limiting toxicity (DLT) was reached, with three of six patients having grade 4 neutropenia. At 1.65 mg/m2, one of seven patients had grade 4 neutropenia. Nonhematologic toxicity was modest, with diarrhea > or = grade 3 in two patients and lethargy > or = grade 3 in eight. PK/pharmacodynamic (PD) analyses showed marked interpatient variability. Steady-state concentrations (Css) of 9-AC L > or = 10 nmol/L (3.6 microg/L) were seen in five of seven patients at 1.65 mg/m2 and five of six patients at 1.9 mg/m2. Using the sigmoidal maximal effect (Emax) model, 9-AC L area under the concentration-time curve (AUC) and Css correlated with day 15 decrease in neutrophils (R2 = .47), but not platelets. CONCLUSIONS The recommended phase II dose of 9-AC colloidal dispersion (CD) given as a 24-hour continuous infusion weekly for 4 of every 5 weeks is 1.65 mg/m2.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D012044 Regression Analysis Procedures for finding the mathematical function which best describes the relationship between a dependent variable and one or more independent variables. In linear regression (see LINEAR MODELS) the relationship is constrained to be a straight line and LEAST-SQUARES ANALYSIS is used to determine the best fit. In logistic regression (see LOGISTIC MODELS) the dependent variable is qualitative rather than continuously variable and LIKELIHOOD FUNCTIONS are used to find the best relationship. In multiple regression, the dependent variable is considered to depend on more than a single independent variable. Regression Diagnostics,Statistical Regression,Analysis, Regression,Analyses, Regression,Diagnostics, Regression,Regression Analyses,Regression, Statistical,Regressions, Statistical,Statistical Regressions
D002166 Camptothecin An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. Camptothecine
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D003102 Colloids Two-phase systems in which one is uniformly dispersed in another as particles small enough so they cannot be filtered or will not settle out. The dispersing or continuous phase or medium envelops the particles of the discontinuous phase. All three states of matter can form colloids among each other. Hydrocolloids,Colloid,Hydrocolloid
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females

Related Publications

L L Siu, and A M Oza, and E A Eisenhauer, and P S Firby, and J J Thiessen, and M Michael, and N Wainman, and J Manzo, and R Feld, and R A Goldberg, and M J Moore
A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion.
October 2003, Cancer chemotherapy and pharmacology,
L L Siu, and A M Oza, and E A Eisenhauer, and P S Firby, and J J Thiessen, and M Michael, and N Wainman, and J Manzo, and R Feld, and R A Goldberg, and M J Moore
Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.
April 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
L L Siu, and A M Oza, and E A Eisenhauer, and P S Firby, and J J Thiessen, and M Michael, and N Wainman, and J Manzo, and R Feld, and R A Goldberg, and M J Moore
Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.
December 2001, Clinical cancer research : an official journal of the American Association for Cancer Research,
L L Siu, and A M Oza, and E A Eisenhauer, and P S Firby, and J J Thiessen, and M Michael, and N Wainman, and J Manzo, and R Feld, and R A Goldberg, and M J Moore
A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients.
July 2002, Clinical cancer research : an official journal of the American Association for Cancer Research,
L L Siu, and A M Oza, and E A Eisenhauer, and P S Firby, and J J Thiessen, and M Michael, and N Wainman, and J Manzo, and R Feld, and R A Goldberg, and M J Moore
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
May 1999, Annals of oncology : official journal of the European Society for Medical Oncology,
L L Siu, and A M Oza, and E A Eisenhauer, and P S Firby, and J J Thiessen, and M Michael, and N Wainman, and J Manzo, and R Feld, and R A Goldberg, and M J Moore
Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
June 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
L L Siu, and A M Oza, and E A Eisenhauer, and P S Firby, and J J Thiessen, and M Michael, and N Wainman, and J Manzo, and R Feld, and R A Goldberg, and M J Moore
Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.
February 1998, Clinical cancer research : an official journal of the American Association for Cancer Research,
L L Siu, and A M Oza, and E A Eisenhauer, and P S Firby, and J J Thiessen, and M Michael, and N Wainman, and J Manzo, and R Feld, and R A Goldberg, and M J Moore
A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients.
September 2001, Cancer chemotherapy and pharmacology,
L L Siu, and A M Oza, and E A Eisenhauer, and P S Firby, and J J Thiessen, and M Michael, and N Wainman, and J Manzo, and R Feld, and R A Goldberg, and M J Moore
Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
March 1994, Cancer research,
L L Siu, and A M Oza, and E A Eisenhauer, and P S Firby, and J J Thiessen, and M Michael, and N Wainman, and J Manzo, and R Feld, and R A Goldberg, and M J Moore
Phase I study of weekly maytansine given by iv bolus or 24-hour infusion.
January 1979, Cancer treatment reports,
Copied contents to your clipboard!